Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options. Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation. Come join us and be a part of the ground-breaking team set to unlock the power of targeted radiotherapy!

Our mission: Develop innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases. The premier biotherapeutic targeting company. Our powerful Abileap™ discovery engine combines massively parallel, continuously learning AI with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multispecific antibodies of exquisite selectivity and affinity. The antibodies respond to environmental signals within the cellular microenvironment, generating logic-gated therapeutics. We are dedicated to developing the most potent and selective antibody therapeutics for areas of great unmet need.

Amplitude Ventures is a capital catalyst for highly innovative companies at the point of value acceleration. We work with Canada's most promising healthcare companies that share our vision of bringing groundbreaking technologies to patients. Amplitude is focused on building world-class Canadian companies in precision medicine and next-generation medical devices. Since 2012, the Amplitude team has deployed a venture growth model used to build Canadian companies with world-class management teams and scale companies to breakout potential. This model has been used by the team to create, build, and grow companies, resulting in over $1 billion in company value. Our offices are in Montreal, Toronto, and Vancouver.

Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter.

Deep Genomics is using Artificial Intelligence to build a new universe of life-saving genetic therapies. The future of medicine will rely on Artificial Intelligence, because biology is too complex for humans to understand. At Deep Genomics, our geneticists, molecular biologists, and chemists develop new ways of detecting and treating disease using our biologically accurate Artificial Intelligence technology.

DrugBank is the world’s first intelligent and comprehensive drug knowledge platform. With the help of Artificial Intelligence, our team of medical and scientific experts gather, author, verify, and structure all of the latest biomedical information into one knowledge platform. Then we make this platform easy to access through DrugBank Online (our free-to-use website), data downloads, or software integrations. Our goal is to augment human intelligence so that all medical information is used to its fullest potential, because we want to ensure that everyone in the world has access to the best possible medical outcomes.

Chronic inflammatory diseases are the most significant cause of death in the world, and those who live with them have a reduced quality of life. Many immunology-focused medications give patients a temporary fix to a longer-term problem—addressing symptom control rather than the root cause of disease. Evommune is different. We strive to develop accessible innovations that are meant to address symptoms as well as help avoid disease progression and medical complications in the future.

Fluid biomed is a medical device start-up founded by two neurosurgeons at the university of calgary that has developed an implantable dissolving stent to divert blood flow and heal blood vessels. The desire to innovate and create positive change has always been a priority for the founders and inventors, dr. John wong and dr. Alim mitha. Working together for the past 18 years to help people with stroke, their drive and commitment to improve patient health sparked a vision to create a radical new stent to cure brain aneurysms without invasive surgery.

Gandeeva Therapeutics is a precision biotechnology company integrating the power of Cryogenic Electron Microscopy (CRYO-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva’s structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT™), hit identification by screening virtual and fragment libraries (HYPERFOCUS™), and lead optimization (CRYO-CADD™). Gandeeva has a robust preclinical oncology pipeline targeting difficult-to-treat cancers with novel protein interaction modulators such as interfacial glues (IGLUES™) and allosteric inhibitors. Gandeeva is headquartered in the Greater Vancouver area, Canada.

Nomic (formerly Nplex Biosciences) is a bioengineering company working to make the human proteome as broadly and easily accessible as the human genome. We are building the NELISA, a next-generation ELISA platform for measuring proteins at scale and at high throughput. The NELISA was designed to seamlessly integrate into current workflows in biology and is uniquely adaptable to a wide variety of use cases within drug and biomarker development workflows. Nomic is headquartered in Montreal, with labs and offices in Boston. For more information, visit www.nomic.bio.

Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for the treatment of Huntington’s disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 Healey Platform trial. The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018. The company is based in Naarden, the Netherlands, Herzliya, Israel, and Boston, MA in the U.S.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to discovering and developing novel therapeutics. We use our genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Our company was founded in 2016 by field-leading academics to systematically employ synthetic lethality insights and platforms and develop new precision oncology medicines. For more information, please visit www.reparerx.com. Scam Prevention Notice It has come to our attention that individuals posing as representatives of Repare Therapeutics have been engaging in fraudulent recruiting activities, offering fake job opportunities to unsuspecting candidates. These scams are designed to deceive job seekers into providing personal information or financial details under false pretenses.